Figure 2.

Aerosolization and the prophylactic and therapeutic efficacy of R14 against SARS-CoV-2

(A) Schematic layout of the whole-body exposure platform.

(B) Aerosol size distributions of six monitoring points in the exposure chamber (red triangles in A).

(C) Aerosol mass concentration as a function of time when the flowrate of the carrier air was 5, 10, or 20 LPM.

(D) Neutralization of SARS-CoV-2 pseudotyped virus by R14 and S43 post-aerosolization in Vero cells; n = 3 per nanobody concentration points. Experiments were independently repeated twice with similar results, and one representative curve is displayed.

(E) Viral RNA loads in the lungs of mice treated with a single dose of 0.25 or 5 mg/kg R14 by the i.n. route and i.h. route prior to SARS-CoV-2 infection, respectively.

(F) Viral RNA loads in the lungs of mice treated with 0.75 mg/kg of R14 at 10 min, 1.5 h, and 7 h by the i.h. route post-SARS-CoV-2 infection.

Two-tailed ordinary one-way ANOVA with Sidak’s multiple comparisons was used in the statistical analyses for (E) and (F).